C3 Jian, West China School of Stomatology to create joint CRC to test oral healthcare products

C3 Jian, Inc.'s Board of Directors today announced that the Company has signed an agreement with the West China School of Stomatology at Sichuan University ("West China") to create a joint Clinical Research Centre (CRC) to test new oral healthcare products in human clinical trials. The C3 Jian/West China CRC will be located in West China's facilities in Chengdu, China. C3 Jian's wholly owned subsidiary, Sen Nuo Wei Biotechnology Co, Ltd., based in Chengdu, was also a party to the agreement. The newly created CRC will be a strategically important site for C3 Jian as it moves its products from research to clinical development. West China, the first and largest dental university in China, has agreed to develop and operate the CRC under U.S. Food and Drug Administration Good Clinical Practices (GCP).

“The ability to work with an institution as prestigious as West China is truly an honor for our Company”

"We are very excited about this new partnership with West China," said Todd R. Patrick, C3 Jian President and CEO. "We are both focused on improving oral healthcare on a worldwide basis, and we believe that having the CRC will be an important asset for us as we strive to bring our products to the marketplace. It is particularly critical and noteworthy that West China has agreed that it will operate the CRC and the studies run within the CRC under FDA defined GCP. As such, the clinical trial data we generate in collaboration with West China will have application toward worldwide regulatory approvals and product registrations."

C3 Jian expects the first clinical trial undertaken at the CRC will be directed toward its Sm STAMPS product targeting dental caries (tooth decay). Dental caries is a multibillion-dollar annual burden on healthcare systems worldwide. In the U.S. alone, annual dental expenditures related to the bacteria that causes dental caries is estimated to exceed $50 billion. It is also a significant problem in China. C3 Jian is developing the first specifically targeted drug to eliminate dental caries. The product is expected to be administered in the form of a mouth wash.

"We are delighted to partner with our friends at C3 Jian in this endeavor," stated Dean of West China School of Stomatology, Sichuan University, Zhou Xuedong, D.D.S., Ph.D. "Bringing new, cutting-edge technologies to deliver improved oral healthcare to the people of Sichuan Province is extremely exciting and consistent with our mission. For over 100 years, our university has been a leader in dental teaching and clinical care. This new endeavor will broaden our reach to the highest possible standards of clinical research with applications on a worldwide basis."

The initial human oral health clinical trials at the CRC will be related to C3 Jian products but the CRC has the potential to expand its capacity beyond C3 products to test other solutions that address unmet needs in oral health. C3 Jian has a right of first refusal to utilize the space at the CRC, which will be owned by West China. Over time, the parties expect that other companies and institutions will be able to take advantage of the capabilities and expertise that will be resident at the CRC.

"The ability to work with an institution as prestigious as West China is truly an honor for our Company," stated Dr. Wenyuan Shi, C3 Jian Chief Scientific Officer and Co-Founder. "This is one of the finest dental universities in the world, and the ability to work with Dean and Professor Zhou Xuedong and her talented faculty and staff to help bring our new approaches to oral healthcare management into practice is a real benefit for C3. We look forward to creating a long-term and mutually beneficial partnership."